Emory Center for Psychedelics and Spirituality

Ganz, P.A. The 'three Ps' of cancer survivorship care. BMC Med 9, 14, doi: 10.1186/1741-7015-9-14 (2011).

Passie, T., Seifert, J., Schneider, U. & Emrich, H.M. The pharmacology of psilocybin. Addict Biol 7, 357-364, doi: 10.1080/1355621021000005937 (2002).

Phelps, J. Developing Guidelines and Competencies for the Training of Psychedelic Therapists. Journal of Humanistic Psychology 57, 450-487, doi: 10.1177/0022167817711304 (2017).

Rosenbaum, D. et al. Psychedelics for psychological and existential distress in palliative and cancer care. Current oncology (Toronto, Ont.) 26, 225-226, doi: 10.3747/co.26.5009 (2019).

Engel, G.L. A life setting conducive to illness: The giving-up--given-up complex. Bull Menninger Clin 32, 355-365 (1968).

Grassi, L. & Nanni, M.G. Demoralization syndrome: New insights in psychosocial cancer care. Cancer 122, 2130-2133, doi: 10.1002/cncr.30022 (2016).

Robinson, S., Kissane, D.W., Brooker, J. & Burney, S. A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: A decade of research. Journal of pain and symptom management 49, 595-610, doi: 10.1016/j.jpainsymman.2014.07.008 (2015).

van der Spek, N. et al. Cost-utility analysis of meaning-centered group psychotherapy for cancer survivors. Psycho-oncology 27, 1772-1779, doi: 10.1002/pon.4726 (2018).

Spiegel, D. & Yalom, I.D. A support group for dying patients. Int J Group Psychother 28, 233-245, doi: 10.1080/00207284.1978.11491609 (1978).

Spiegel, D. Psilocybin-assisted psychotherapy for dying cancer patients - aiding the final trip. J Psychopharmacol 30, 1215-1217, doi: 10.1177/0269881116675783 (2016).

Spiegel, D. & Cordova, M. Supportive-expressive group therapy and life extension of breast cancer patients: Spiegel et al. (1989). Adv Mind Body Med 17, 38-41 (2001).

Zaider, T.I., Kissane, D.W., Schofield, E., Li, Y. & Masterson, M. Cancer-related communication during sessions of family therapy at the end of life. Psychooncology 29, 373-380, doi: 10.1002/pon.5268 (2020).

Anderson, B.T. et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine, 100538, doi: 10.1016/j.eclinm.2020.100538 (2020).

Whelan, A. & Johnson, M.I. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? Pain Manag 8, 217-229, doi: 10.2217/pmt-2017-0068 (2018).

Kast, E.C. & Collins, V.J. STUDY OF LYSERGIC ACID DIETHYLAMIDE AS AN ANALGESIC AGENT. Anesth Analg 43, 285-291 (1964).

Grof, S., Goodman, L.E., Richards, W.A. & Kurland, A.A. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 8, 129-144, doi: 10.1159/000467984 (1973).

Chwistek, M. & Ewerth, N. Opioids and chronic pain in cancer survivors: Evolving practice for palliative care clinics. J Palliat Med 19, 254, doi: 10.1089/jpm.2015.0471 (2016).

Paice, J.A. et al. Management of chronic pain in survivors of adult cancers: American society of clinical oncology clinical practice guideline. Journal of Clinical Oncology 34, 3325-3345, doi: 10.1200/jco.2016.68.5206 (2016).

Temel, J.S., Shaw, A.T. & Greer, J.A. Challenge of prognostic uncertainty in the modern era of cancer therapeutics. Journal of Clinical Oncology 34, 3605-3608, doi: 10.1200/JCO.2016.67.8573 (2016).

Sledge, G.W. Patients and physicians in the era of modern cancer care. JAMA 321, 829-830, doi: 10.1001/jama.2018.17334 (2019).

Stern, A.P. Surviving cancer in the midst of a treatment revolution: Hope and delusion. JAMA Oncology 4, 1667, doi: 10.1001/jamaoncol.2018.4430 (2018).

Langbaum, T. & Smith, T.J. Time to study metastatic-cancer survivorship. The New England Journal of Medicine 380, 1300-1302, doi: 10.1056/NEJMp1901103 (2019).

Swift, T.C. et al. Cancer at the dinner table: Experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. Journal of Humanistic Psychology 57, 488-519, doi: 10.1177/0022167817715966 (2017).

Marzorati, C., Riva, S. & Pravettoni, G. Who is a cancer survivor? A systematic review of published definitions. J Cancer Educ 32, 228-237, doi: 10.1007/s13187-016-0997-2 (2017).

Geerse, O.P., Lakin, J.R., Berendsen, A.J., Alfano, C.M. & Nekhlyudov, L. Cancer survivorship and palliative care: Shared progress, challenges, and opportunities. Cancer 124, 4435-4441, doi: 10.1002/cncr.31723 (2018).

Halpern, M.T. et al. Models of cancer survivorship care: Overview and summary of current evidence. Journal of Oncology Practice 11, e19-27, doi: 10.1200/jop.2014.001403 (2015).

Shakeel, S., Tung, J., Rahal, R. & Finley, C. Evaluation of factors associated with unmet needs in adult cancer survivors in Canada. JAMA Netw Open 3, e200506, doi: 10.1001/jamanetworkopen.2020.0506 (2020).

Yazdani, S. & Abdi, S. Brief review: Pain management for cancer survivors: Challenges and opportunities. Can J Anaesth 61, 745-753, doi: 10.1007/s12630-014-0170-5 (2014).

Mollica, M. & Nemeth, L. Transition from patient to survivor in African American breast cancer survivors. Cancer Nurs 38, 16-22, doi: 10.1097/ncc.0000000000000120 (2015).

Schenker, Y., Merlin, J.S. & Quill, T.E. Use of palliative care earlier in the disease course in the context of the opioid epidemic: Educational, research, and policy issues. JAMA 320, 871-872, doi: 10.1001/jama.2018.9739 (2018).

Vehling, S. & Philipp, R. Existential distress and meaning-focused interventions in cancer survivorship. Curr Opin Support Palliat Care 12, 46-51, doi: 10.1097/spc.0000000000000324 (2018).

Strang, P., Strang, S., Hultborn, R. & Arnér, S. Existential pain--an entity, a provocation, or a challenge? Journal of Pain and Symptom Management 27, 241-250, doi: 10.1016/j.jpainsymman.2003.07.003 (2004).

LeMay, K. & Wilson, K.G. Treatment of existential distress in life threatening illness: A review of manualized interventions. Clin Psychol Rev 28, 472-493, doi: 10.1016/j.cpr.2007.07.013 (2008).

Kissane, D.W. Demoralization: A life-preserving diagnosis to make for the severely medically ill. J Palliat Care 30, 255-258, doi: 10.1177/082585971403000402 (2014).

Townsend, K. Demoralisation in palliative care. The Lancet. Oncology 19, 168, doi: 10.1016/s1470-2045(18)30020-2 (2018).

Jong, C., Kissane, D., Geessink, R. & Velden, D. Demoralization in opioid dependent patients: A comparative study with cancer patients and community subjects. The Open Addiction Journal 1, doi: 10.2174/1874941000801010007 (2008).

de Figueiredo, J.M. & Griffith, J.L. Chronic pain, chronic demoralization, and the role of psychotherapy. Journal of Contemporary Psychotherapy 46, 167-177, doi: 10.1007/s10879-016-9331-x (2016).

Frank, J. The role of hope in psychotherapy. Int J Psychiatry 5, 383-395 (1968).

Ferrer, R.A. & Padgett, L.S. Leveraging affective science to maximize the effectiveness of palliative care. Journal of Clinical Oncology 33, 4229-4230, doi: 10.1200/jco.2015.62.8883 (2015).

Clarke, D.M. & Kissane, D.W. Demoralization: Its phenomenology and importance. Aust N Z J Psychiatry 36, 733-742, doi: 10.1046/j.1440-1614.2002.01086.x (2002).

Robinson, S. et al. Refinement and revalidation of the demoralization scale: The DS-II-external validity. Cancer 122, 2260-2267, doi: 10.1002/cncr.30012 (2016).

Belar, A. et al. Multicenter study of the psychometric properties of the new demoralization scale (DS-II) in Spanish-speaking advanced cancer patients. Journal of Pain and Symptom Management 57, 627-634, doi: 10.1016/j.jpainsymman.2018.11.016 (2019).

Kissane, D.W. The contribution of demoralization to end of life decisionmaking. Hastings Cent Rep 34, 21-31, doi: 10.2307/3528690 (2004).

Ong, C.K. & Forbes, D. Embracing Cicely Saunders's concept of total pain. BMJ 331, 576, doi: 10.1136/bmj.331.7516.576-d (2005).

de Figueiredo, J.M. Demoralization and psychotherapy: A tribute to Jerome D. Frank, MD, PhD (1909-2005). Psychother Psychosom 76, 129-133, doi: 10.1159/000099839 (2007).

Robinson, S., Kissane, D.W., Brooker, J., Hempton, C. & Burney, S. The relationship between poor quality of life and desire to hasten death: A multiple mediation model examining the contributions of depression, demoralization, loss of control, and low self-worth. Journal of Pain and Symptom Management 53, 243-249, doi: 10.1016/j.jpainsymman.2016.08.013 (2017).

Byock, I. Taking psychedelics seriously. J Palliat Med 21, 417-421, doi: 10.1089/jpm.2017.0684 (2018).

Meier, D.E. et al. A national strategy for palliative care. Health Aff (Millwood) 36, 1265-1273, doi: 10.1377/hlthaff.2017.0164 (2017).

Kelley, A.S. & Morrison, R.S. Palliative care for the seriously ill. The New England Journal of Medicine 373, 747-755 (2015).

Kavalieratos, D. et al. Association between palliative care and patient and caregiver outcomes: A systematic review and meta-analysis. JAMA 316, 2104-2114, doi: 10.1001/jama.2016.16840 (2016).

Rabow, M. et al. Moving upstream: A review of the evidence of the impact of outpatient palliative care. J Palliat Med 16, 1540-1549, doi: 10.1089/jpm.2013.0153 (2013).

Temel, J.S. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. The New England Journal of Medicine 363, 733-742, doi: 10.1056/NEJMoa1000678 (2010).

Sinclair, C.T. How palliative care can help patients into survivorship. Master Clinician Series: Survivorship and Upstream Palliative Care (2020).

Ferrell, B.R., Twaddle, M.L., Melnick, A. & Meier, D.E. National consensus project clinical practice guidelines for quality palliative care guidelines, 4th edition. J Palliat Med 21, 1684-1689, doi: 10.1089/jpm.2018.0431 (2018).

Ahluwalia, S.C. et al. A systematic review in support of the national consensus project clinical practice guidelines for quality palliative care, fourth edition. Journal of Pain and Symptom Management 56, 831-870, doi: 10.1016/j.jpainsymman.2018.09.008 (2018).

Chwistek, M. Recent advances in understanding and managing cancer pain. F1000Res 6, 945, doi: 10.12688/f1000research.10817.1 (2017).

van den Beuken-van Everdingen, M.H., Hochstenbach, L.M., Joosten, E.A., Tjan-Heijnen, V.C. & Janssen, D.J. Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. Journal of Pain and Symptom Management 51, 1070-1090.e1079, doi: 10.1016/j.jpainsymman.2015.12.340 (2016).

Bhatnagar, S. & Gupta, M. Evidence-based clinical practice guidelines for interventional pain management in cancer pain. Indian J Palliat Care 21, 137-147, doi: 10.4103/0973-1075.156466 (2015).

Meuser, T. et al. Symptoms during cancer pain treatment following WHO-guidelines: A longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93, 247-257, doi: 10.1016/s0304-3959(01)00324-4 (2001).

Bruera, E. & Del Fabbro, E. Pain management in the era of the opioid crisis. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 38, 807-812, doi: 10.1200/edbk_208563 (2018).

Arthur, J. & Bruera, E. Balancing opioid analgesia with the risk of nonmedical opioid use in patients with cancer. Nature reviews. Clinical Oncology 16, 213-226, doi: 10.1038/s41571-018-0143-7 (2019).

Loren, A.W. Harder to treat than leukemia - Opioid use disorder in survivors of cancer. The New England Journal of Medicine 379, 2485-2487, doi: 10.1056/NEJMp1812850 (2018).

Arthur, J.A. et al. Aberrant opioid use and urine drug testing in outpatient palliative care. J Palliat Med 19, 778-782, doi: 10.1089/jpm.2015.0335 (2016).

Arthur, J. et al. Outcomes of a specialized interdisciplinary approach for patients with cancer with aberrant opioid-related behavior. The Oncologist 23, 263-270, doi: 10.1634/theoncologist.2017-0248 (2018).

Merlin, J.S. et al. Managing opioids, including misuse and addiction, in patients with serious illness in ambulatory palliative care: A qualitative study. The American Journal of Hospice & Palliative Care 37, 507-513, doi: 10.1177/1049909119890556 (2020).

Merlin, J.S., Childers, J. & Arnold, R.M. Chronic pain in the outpatient palliative care clinic. The American Journal of Hospice & Palliative Care 30, 197-203, doi: 10.1177/1049909112443587 (2013).

Goodlev, E.R. et al. Managing cancer pain, monitoring for cancer recurrence, and mitigating risk of opioid use disorders: A team-based, interdisciplinary approach to cancer survivorship. J Palliat Med 22, 1308-1317, doi: 10.1089/jpm.2019.0171 (2019).

Flanagan, T.W. & Nichols, C.D. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry 30, 363-375, doi: 10.1080/09540261.2018.1481827 (2018).

Castellanos, J.P. et al. Chronic pain and psychedelics: A review and proposed mechanism of action. Reg Anesth Pain Med 45, 486-494, doi: 10.1136/rapm-2020-101273 (2020).

Karst, M., Halpern, J.H., Bernateck, M. & Passie, T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series. Cephalalgia 30, 1140-1144, doi: 10.1177/0333102410363490 (2010).

Sewell, R.A., Halpern, J.H. & Pope, H.G., Jr. Response of cluster headache to psilocybin and LSD. Neurology 66, 1920-1922, doi: 10.1212/01.wnl.0000219761.05466.43 (2006).

Ramachandran, V., Chunharas, C., Marcus, Z., Furnish, T. & Lin, A. Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase 24, 105-110, doi: 10.1080/13554794.2018.1468469 (2018).

Dyck, E. Psychedelics and dying care: A historical look at the relationship between psychedelics and palliative care. J Psychoactive Drugs 51, 102-107, doi: 10.1080/02791072.2019.1581308 (2019).

Kelmendi, B., Corlett, P., Ranganathan, M., D'Souza, C. & Krystal, J.H. The role of psychedelics in palliative care reconsidered: A case for psilocybin. J Psychopharmacol 30, 1212-1214, doi: 10.1177/0269881116675781 (2016).

Back, A.L. What psilocybin taught me, one year later. J Palliat Med 23, 1130-1131, doi: 10.1089/jpm.2020.0018 (2020).

Cancer and hallucinogens: A long, strange trip. The Lancet. Oncology 11, 603, doi: 10.1016/s1470-2045(10)70153-4 (2010).

VanderWeele, T.J. On the promotion of human flourishing. Proc Natl Acad Sci U S A 114, 8148-8156, doi: 10.1073/pnas.1702996114 (2017).

Haufe, M., Leget, C., Potma, M. & Teunissen, S. How can existential or spiritual strengths be fostered in palliative care? An interpretative synthesis of recent literature. BMJ Support Palliat Care, doi: 10.1136/bmjspcare-2020-002379 (2020).

Nolan, S. Hope beyond (redundant) hope: how chaplains work with dying patients. Palliat Med 25, 21-25, doi: 10.1177/0269216310380297 (2011).

Jacobs, M.R. What are we doing here? Chaplains in contemporary health care. Hastings Cent Rep 38, 15-18, doi: 10.1353/hcr.0.0079 (2008).

Idler, E.L., Grant, G.H., Quest, T., Binney, Z. & Perkins, M.M. Practical matters and ultimate concerns, “doing,” and “being”: A diary study of the chaplain's role in the care of the seriously ill in an urban acute care hospital. Journal for the Scientific Study of Religion 54, 722-738, doi: 10.1111/jssr.12235 (2015).

Center for Contemplative Science and Compassion-Based Ethics, Emory University

Cockram, C.A., Doros, G. & de Figueiredo, J.M. Diagnosis and measurement of subjective incompetence: The clinical hallmark of demoralization. Psychother Psychosom 78, 342-345, doi: 10.1159/000235737 (2009).

Gardner, C. & Kleinman, A. Medicine and the mind - The consequences of psychiatry's identity crisis. The New England Journal of Medicine 381, 1697-1699, doi: 10.1056/NEJMp1910603 (2019).

Johnson, M., Richards, W. & Griffiths, R.R. Human hallucinogen research: Guidelines for safety. J Psychopharmacol 22, 603-620, doi: 10.1177/0269881108093587 (2008).

Yaden, D.B. et al. The development of the Awe Experience Scale (AWE-S): A multifactorial measure for a complex emotion. The Journal of Positive Psychology 14, 474-488, doi: 10.1080/17439760.2018.1484940 (2019).

Barrett, F.S., Bradstreet, M.P., Leoutsakos, J.S., Johnson, M.W. & Griffiths, R.R. The challenging experience questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30, 1279-1295, doi: 10.1177/0269881116678781 (2016).

Roseman, L. et al. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. J Psychopharmacol 33, 1076-1087, doi: 10.1177/0269881119855974 (2019).

Zigmond, A.S. & Snaith, R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67, 361-370, doi: 10.1111/j.1600-0447.1983.tb09716.x (1983).

Barrett, F.S. & Griffiths, R.R. Classic hallucinogens and mystical experiences: Phenomenology and neural rorrelates. Curr Top Behav Neurosci 36, 393-430, doi: 10.1007/7854_2017_474 (2018).

Barrett, F.S., Johnson, M.W. & Griffiths, R.R. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29, 1182-1190, doi: 10.1177/0269881115609019 (2015).

Kaur, N. et al. Evaluation of a modified version of the Posttraumatic Growth Inventory-Short Form. BMC Med Res Methodol 17, 69, doi: 10.1186/s12874-017-0344-2 (2017).

Lee, R. & Robbins, S. Measuring belongingness: The Social Connectedness and the Social Assurance Scales. Journal of Counseling Psychology 42, 232-241, doi: 10.1037/0022-0167.42.2.232 (1995).

Mundt, J.C., Marks, I.M., Shear, M.K. & Greist, J.H. The Work and Social Adjustment Scale: A simple measure of impairment in functioning. Br J Psychiatry 180, 461-464, doi: 10.1192/bjp.180.5.461 (2002).

Morgan, C., McAndrew, A., Stevens, T., Nutt, D., & Lawn, W. Tripping up addiction: The use of psychedelic drugs in the treatment of problematic drug and alcohol use. Current Opinion in Behavioral Sciences 13, 71-76, doi: 10.1016/j.cobeha.2016.10.009 (2017).

Perkins, D., et al. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. Australian and New Zealand Journal of Psychiatry 55, 1127-1133, doi: 10.1177/0004867421998785 (2021).

Beachy, J. Tending the sacred: The emerging role of professional chaplaincy in psychedelic-assisted therapies. MAPS Bulletin 2021 31, No. 2.

MAPS Bulletin Winter 2021: Vol 31, No. 1

Lehrner, A. & Yehuda, R. Moral injury and the promise of MDMA-assisted therapy for PTSD. MAPS Bulletin Winter 2021 31, No. 1.

Maia, L.O., Beaussant, Y., & Garcia, A.C.M. The therapeutic potential of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness: A systematic review. Journal of Pain and Symptom Management 63, 725-738, doi: 10.1016/j.jpainsymman.2022.01.024 (2022).

Marseille, E., Kahn, J.G., Yazar-Klosinski, B., Doblin, R., & Doering, S. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PloS One 15, e0239997–e0239997, doi: 10.1371/journal.pone.0239997 (2020).

Griffiths, R.R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 30, 1181-1197, doi: 10.1177/0269881116675513 (2016).

Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30, 1165-1180, doi: 10.1177/0269881116675512 (2016).

van der Spek, N. et al. Efficacy of meaning-centered group psychotherapy for cancer survivors: A randomized controlled trial. Psychological Medicine 47, 1990-2001, doi: 10.1017/s0033291717000447 (2017).

Wolfson, P.E., Andries, J., Feduccia, A.A. et al. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: A randomized pilot study. Sci Rep 10, 20442, doi: 10.1038/s41598-020-75706-1 (2020).

Pollan, M. How to change your mind: What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence (2018).

Medicine, I. o. & Council, N. R. From cancer patient to cancer survivor: Lost in transition. (The National Academies Press, 2006).

Frankl, V.E., Lasch, I., Kushner, H.S. & Winslade, W.J. Man's search for meaning (2006).

Yalom, I.D. Existential psychotherapy (1980).